Table 2. Tumour phenotype according to stage.
| Tumour characteristic | Stages I–II, n=19 (30%) | Stage III, n=22 (35%) | Stage IV, n=20 (32%) | P value |
|---|---|---|---|---|
| Poorly differentiated (n=13) |
1 (8%) |
6 (46%) |
6 (46%) |
0.10 |
| P53 overexpression (n=26) |
14 (54%) |
3 (11%) |
9 (35%) |
<0.001 |
| Abnormal β-catenin (n=12) |
5 (42%) |
3 (25%) |
4 (33%) |
0.61 |
| dMMR phenotype (n=14) |
4 (29%) |
9 (64%) |
1 (7%) |
0.02 |
| Mutated KRAS (n=21a) | 5 (24%) | 8 (38%) | 7 (33%) | 0.79 |
Abbreviation: dMMR=mismatch repair deficiency.
a
One tumour of undetermined stage was locally advanced.